This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Novartis brief argues lower court was right to dismiss Gleevec pay-for-delay case

( January 26, 2018, 23:31 GMT | Official Statement) -- MLex Summary: Novartis filed a brief in response to plaintiffs’ appeal of the order that dismissed antitrust claims Norvatis over the drug Gleevec. “The end payor plaintiffs’ amended complaint does not allege facts that would permit the inference that a reasonable litigant would have concluded that it would be frivolous to defend the Gleevec patent; it alleges no prior finding of any kind that establishes, or even casts doubt on, the patent’s validity,” argues Novartis.See document below....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Documents

Related Sections